AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  title={AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.},
  author={Pasi Antero J{\"a}nne and James C Yang and Dong-Wan Kim and David Planchard and Yuichiro Ohe and Suresh S Ramalingam and Myung-ju Ahn and S Kim and W Su and Leora A Horn and Daniel E. Haggstrom and E Felip and Joo Hang Kim and Paul I H Frewer and Mireille V. Cantarini and Kathryn H. Brown and Paul Alfred Dickinson and Serban Ghiorghiu and Malcolm Ranson},
  journal={The New England journal of medicine},
  volume={372 18},
BACKGROUND The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer). In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations. METHODS We administered AZD9291 at doses of 20 to 240 mg once daily in patients with… CONTINUE READING
Highly Influential
This paper has highly influenced 38 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 24 times over the past 90 days. VIEW TWEETS
423 Citations
27 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 423 extracted citations


Publications referenced by this paper.
Showing 1-10 of 27 references

A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC)

  • HA Wakelee, SN Gettinger, JA Engelman
  • J Clin Oncol 2010; 28:Suppl:3017. abstract…
  • 2015

who previously controlled to gefitinib : a single - arm , open - label , phase II study

  • JA Engelman, K Zejnullahu, T Mitsudo-mi
  • 2012

Similar Papers

Loading similar papers…